生物标志物作为药物开发中的替代终点:找到它们的正确位置
1The Degge Group Ltd., Bridge to Data Massachusetts.
Clinical therapeutics
|September 19, 2025
概括
生物标志物和替代终点对于药物开发和临床实践至关重要. 本综述阐明了它们的定义,验证标准和在心血管,抗癌和抗糖尿病药物试验中的现实应用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
- 临床试验 临床试验
背景情况:
- 生物标志物和替代终点在现代药物开发中至关重要.
- 它们的精确定义和验证对于监管批准和临床使用至关重要.
研究的目的:
- 要区分临床和代用终点.
- 定义各种类型的生物标志物.
- 概述替代终点使用的生物标志物验证标准.
主要方法:
- 文献审查和现有知识的综合.
- 对生物标志物的验证标准的分析.
- 药物开发案例的案例研究分析.
主要成果:
- 在临床和代用终点之间建立了明确的区别.
- 生物标志物类型和验证方法详细说明.
- 通过心血管,抗癌和抗糖尿病药物开发示例展示了实际应用.
结论:
- 了解生物标志物和替代终点的作用可以提高药物开发效率.
- 经过验证的替代终点可以加速监管决策.
- 这些概念对于推进跨多种疾病领域的治疗干预至关重要.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Measurement of Bioavailability: Pharmacodynamic Methods
236
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
236
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Bioequivalence of Drugs: Drugs with Multiple Indications
151
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
151
Bioavailability Study Design: Single Versus Multiple Dose Studies
216
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
216


